WEIGHT & METABOLIC RESEARCH
A triple-agonist peptide (GLP-1 + GIP + glucagon) studied for some of the strongest weight-loss and metabolic effects recorded for a peptide.
Retatrutide is an investigational triple-agonist peptide that simultaneously engages the GLP-1, GIP, and glucagon receptors. Phase 3 trials have completed, reporting large reductions in body weight alongside broad metabolic improvements, and it has been in active research-market use for roughly two years. It is not FDA-approved.
Included because it pairs completed Phase 3 human evidence with a specific, well-characterized triple-receptor mechanism and roughly two years of consistent research-market use. It represents the strongest end of the metabolic-research spectrum while remaining investigational.
Engages three metabolic receptors at once: GLP-1 (appetite and gastric emptying), GIP (fat-tissue insulin sensitivity), and glucagon (energy expenditure and fat oxidation).
The glucagon component is the differentiator from GLP-1/GIP-only compounds, adding a metabolic-rate and fat-oxidation dimension alongside appetite reduction.
WHAT THE RESEARCH MEASURED
Findings describe study outcomes, not expected personal results.
Retatrutide is investigational and not FDA-approved for any indication. Phase 3 clinical development has completed. Sold and offered strictly for laboratory and research use.
